VP3-2024: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.

Autor: Le Cesne, A.1 (AUTHOR), Schiffler, C.2 (AUTHOR), Bouche, O.3 (AUTHOR), Brahmi, M.4 (AUTHOR), Duffaud, F.5 (AUTHOR), Toulmonde, M.6 (AUTHOR), Landi, B.7 (AUTHOR), Lahlou, W.8 (AUTHOR), Pannier, D.9 (AUTHOR), Bompas, E.10 (AUTHOR), Bertucci, F.11 (AUTHOR), Chaigneau, L.12 (AUTHOR), Collard, O.13 (AUTHOR), Pracht, M.14 (AUTHOR), Adenis, A.15 (AUTHOR), Ray-Coquard, I.16 (AUTHOR), Metzger, S.17 (AUTHOR), Chabaud, S.18 (AUTHOR), Perol, D.19 (AUTHOR), Blay, J-Y.16 (AUTHOR)
Zdroj: Annals of Oncology. Jun2024, Vol. 35 Issue 6, p576-577. 2p.
Databáze: Academic Search Ultimate